VS-7375 Early ORR Signal Challenges Revolution Medicines, But Pivotal Proof Remains Absent

Verastem's VS-7375 Shows Robust Activity in KRAS G12D mPDAC

Verastem Oncology announced robust clinical activity for its oral KRAS G12D–targeting inhibitor, VS-7375, in the Phase 1/2 TARGET-D 101 trial. The study, which enrolled 295 patients with advanced solid tumors harboring a KRAS G12D mutation, showed a 50% confirmed objective response rate (ORR) in second-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients (4 of 8) receiving 900 mg daily, after an average of 6.4 months. In third- and fourth-line mPDAC, the confirmed ORR was 36% (14 patients). This performance contrasts with Revolution Medicines’ Rasonque, which showed a 24% ORR in G12D mPDAC patients. VS-7375 also demonstrated a favorable safety profile, with low discontinuation rates due to adverse events, and the company plans to advance it into a Phase 3 trial in first-line mPDAC, with FDA sign-off.

• VS-7375 demonstrated compelling efficacy in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients with KRAS G12D mutations. Specifically, 50% of patients (4 of 8) in the second-line setting achieved a confirmed objective response rate (ORR) with 900 mg daily dosing, after an average of 6.4 months. In the third- and fourth-line settings, the confirmed ORR was 36% among 14 patients, highlighting its potential in a difficult-to-treat population.
• The trial reported a favorable safety and tolerability profile for VS-7375. Only 2% of patients discontinued treatment due to adverse events across the TARGET-D trial. The most common treatment-related adverse events (TRAEs) at the 900-mg dose were low-grade nausea, vomiting, and diarrhea. Serious TRAEs occurred in 10% of patients, with 2% experiencing serious gastrointestinal TRAEs, and two deaths were deemed unrelated to treatment.
• Beyond pancreatic cancer, VS-7375 also showed promising activity in other KRAS G12D-mutated advanced solid tumors. Patients with non-small cell lung cancer (NSCLC) treated in the second-line setting or later experienced a 43% confirmed ORR. In colorectal cancer (CRC), 900 mg of VS-7375 combined with anti-EGFR therapy led to a 33% unconfirmed ORR in the third-line setting. Verastem has received FDA sign-off to proceed with a Phase 3 trial in first-line mPDAC, expected to commence by year-end.

Robust Efficacy and Favorable Safety for VS-7375 in mPDAC

Recent clinical investigation into KRAS G12D-targeted therapies has yielded encouraging efficacy signals across several studies in metastatic PDAC, with manageable safety profiles that compare favorably to conventional chemotherapy. The trials below represent a cross-section of allele-specific and combination approaches evaluated in pretreated patient populations.

• GFH375 Phase 1 Trial (NCT06500676): GFH375, an oral KRAS G12D inhibitor targeting both the GTP-bound ("ON") and GDP-bound ("OFF") states, was evaluated in 74 heavily treated patients with KRAS G12D-mutant advanced solid tumors, including 43 with PDAC. The recommended phase 2 dose was declared as 600 mg once daily. No dose-limiting toxicity was observed in the dose-escalation portion and the maximum tolerated dose was not reached. One grade 5 treatment-related adverse event (septic shock) was reported; grade ≥3 treatment-related adverse events occurred in 36.5% (27/74) of patients. In patients with PDAC, the confirmed objective response rate (ORR) was 35.1% (13/37), median duration of response was 5.6 months, median progression-free survival (PFS) was 5.5 months, and median overall survival (OS) was 9.9 months.

• HRS-4642 Plus Adebrelimab Phase 1/2 Trial (NCT06427239): This chemotherapy-free trial evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities and no treatment-related deaths occurred. Hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the recommended phase 2 dose cohort (n = 37), the confirmed ORR was 43.2% (95% CI, 27.1–60.5), disease control rate was 81.1% (95% CI, 64.8–92.0), median duration of response was 6.9 months (95% CI, 4.8–8.6), median PFS was 5.7 months (95% CI, 4.0–7.5), and median OS was 11.5 months (95% CI, 9.2–16.9).

• RNK08954 Phase 1a Study: RNK08954, a potent and selective oral KRAS G12D inhibitor, was evaluated with a median follow-up of 4.85 months across 36 evaluable patients. In patients with PDAC, the unconfirmed ORR was 33.33% in the 1,000–1,200 mg cohort. The study supports clinical potential of RNK08954 as a single agent or in combination in patients with KRAS G12D mutation.

• RASolute-302 Phase III Trial (Daraxonrasib): In this randomized phase III trial, the multiselective pan-RAS (ON) inhibitor daraxonrasib (RMC-6236) was evaluated in second-line metastatic PDAC with oncogenic RAS mutations. Daraxonrasib virtually doubled median OS (13.2 vs. 6.6 months) and improved PFS compared to chemotherapy, establishing a new standard of care in this setting.

VS-7375's Differentiated Profile in the KRAS G12D Landscape

The therapeutic landscape for KRAS G12D-mutant metastatic PDAC has historically been defined by cytotoxic chemotherapy regimens with modest outcomes. Standard-of-care options — including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) — deliver median overall survival figures that underscore the unmet need in this population. In a real-world retrospective analysis of NFF as second- or later-line therapy (n = 161), median OS was 8.1 months and median PFS was 3.4 months, with an objective response rate of only 5% and a disease control rate of 52%. Modified gemcitabine plus nab-paclitaxel in the second-line setting yielded median OS of 7.3–8.0 months depending on performance status, while weekly paclitaxel monotherapy in gemcitabine- and S-1-resistant disease produced a response rate of 4.5%, disease control rate of 27.3%, median PFS of 1.7 months, and median OS of 4.6 months. Retrospective data on trametinib combined with hydroxychloroquine or CDK4/6 inhibitors as third- or later-line therapy showed median PFS of 2.0 and 2.8 months and median OS of 4.2 and 4.7 months, respectively, suggesting limited benefit beyond second line with non-targeted approaches.

Against this backdrop, investigational KRAS G12D-directed therapies are demonstrating substantially improved efficacy signals in early-phase trials enriched for KRAS G12D-mutant PDAC. In the phase 1/2 trial of HRS-4642 combined with the PD-L1 inhibitor adebrelimab (NCT06427239; n = 48 pretreated patients), the recommended phase 2 dose cohort (n = 37) achieved a confirmed objective response rate of 43.2% (95% CI, 27.1–60.5), disease control rate of 81.1% (95% CI, 64.8–92.0), median duration of response of 6.9 months (95% CI, 4.8–8.6), median PFS of 5.7 months (95% CI, 4.0–7.5), and median OS of 11.5 months (95% CI, 9.2–16.9), with no treatment-related deaths and no dose-limiting toxicities. The oral KRAS G12D inhibitor GFH375, evaluated in a phase 1 dose-escalation trial (NCT06500676; n = 74 heavily pretreated patients), demonstrated a confirmed ORR of 35.1% (13/37) in PDAC patients, median duration of response of 5.6 months, median PFS of 5.5 months, and median OS of 9.9 months as monotherapy, with the recommended phase 2 dose declared at 600 mg once daily. Similarly, RNK08954 in a phase 1a study reported an unconfirmed ORR of 33.33% in PDAC patients in the 1000–1200 mg cohort. The phase III RASolute-302 trial of daraxonrasib (RMC-6236), a pan-RAS (ON) inhibitor, virtually doubled median OS (13.2 vs. 6.6 months) and improved PFS compared with chemotherapy in second-line metastatic PDAC with oncogenic RAS mutations, establishing a new standard of care in that setting.

Mechanistic and preclinical data further contextualize the rationale for combination strategies in KRAS G12D-mutant PDAC. Acquired resistance to HRS-4642 has been observed clinically (NCT06520488), with reactivation of the unfolded protein response via the MEK/ERK pathway identified as a key resistance mechanism; nimotuzumab was found to synergize strongly with HRS-4642 by sustaining suppression of the MEK/ERK/UPR axis and exacerbating endoplasmic reticulum stress, reversing resistance both in vitro and in vivo. This mechanistic rationale underpins the ongoing phase Ib/II trial of HRS-4642 plus nimotuzumab (NCT06773130), which targets patients with KRAS G12D-mutant recurrent or metastatic PDAC refractory to standard therapy, with HRS-4642 initiated at 1,200 mg Q2W and nimotuzumab at 400 mg weekly. Preclinical combination work with MRTX1133 has also demonstrated that dual inhibition of KRAS G12D and PI3K/BRD4 (via MDP5 nanoparticles) or co-targeting with BCL-xL PROTAC DT2216 and mTOR inhibitor everolimus significantly potentiates apoptosis and overcomes acquired resistance in KRAS G12D-mutant PDAC models, outperforming gemcitabine in orthotopic settings. Collectively, these data position KRAS G12D-directed therapies — particularly in rational combinations — as offering response rates and survival outcomes that meaningfully exceed those achievable with current cytotoxic standards of care in this molecularly defined population.

VS-7375: A New Horizon for KRAS G12D Pancreatic Cancer

The recent announcement regarding Verastem Oncology's VS-7375 represents a significant stride forward in the challenging landscape of pancreatic ductal adenocarcinoma (PDAC). For decades, KRAS G12D, a mutation prevalent in approximately 40% of PDAC cases and associated with particularly poor prognoses, has been considered an 'undruggable' target. The reported 50% confirmed objective response rate in second-line metastatic PDAC patients from the Phase 1/2 TARGET-D 101 trial is a compelling signal, especially when viewed against the backdrop of limited effective treatments for this aggressive cancer. This performance notably surpasses that of other agents in development, underscoring the potential for VS-7375 to emerge as a leading, if not best-in-class, direct KRAS G12D inhibitor.

This breakthrough could fundamentally reshape treatment paradigms, particularly as the company plans to advance into a Phase 3 trial in first-line mPDAC. Such a move, with FDA endorsement, signals a strategic intent to establish VS-7375 as an early-line standard of care, offering new hope to patients who currently face dire prognoses. The favorable safety profile observed thus far further strengthens its competitive positioning.

However, the path forward is not without its complexities. The development of KRAS inhibitors has historically been fraught with challenges, including the potential for a narrow therapeutic index and dose-limiting toxicities, as seen with other G12D inhibitors. While VS-7375's initial safety data are encouraging, continued vigilance in larger trials will be crucial. Moreover, the aggressive biology of KRAS G12D-driven tumors suggests that acquired resistance mechanisms are a significant concern, potentially impacting the long-term durability of responses. Research indicates that combination therapies, perhaps with farnesyl-transferase inhibitors, EGFR inhibitors, or immunotherapies, may be essential to overcome resistance and maximize efficacy. Therefore, while VS-7375 offers a beacon of hope, its ultimate success may lie in its ability to integrate into broader, multi-modal treatment strategies to achieve sustained patient benefit.